Temple University and Fox Chase Cancer Center Researchers Awarded $200,000 in Grants From PA Breast Cancer Coalition

PABCC
Lucia Borriello, PhD, an Assistant Professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University, and Iyad Obeid, PhD, an Associate Professor of Electrical and Computer Engineering at the College of Engineering at Temple University, each received $100,000 research grants from the PA Breast Cancer Coalition.

PHILADELPHIA (April 19, 2024) — Lucia Borriello, PhD, an Assistant Professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University, and Iyad Obeid, PhD, an Associate Professor of Electrical and Computer Engineering at the College of Engineering at Temple University, each received $100,000 research grants today from the PA Breast Cancer Coalition (PBCC).

“I am honored to receive this award from such a prestigious organization that is focused on fighting breast cancer,” said Borriello, who is also a member of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center. Her research focuses on understanding how the tumor microenvironment, which consists of normal cells in the immediate vicinity of cancer cells, promotes breast tumor dormancy and metastasis.

Lucia Borriello

Borriello plans to use the PBCC funding to determine how dormant cancer cells escape the toxicity of chemotherapy treatments, which can lead to stage IV metastatic breast cancer after treatments. Her research will study the mechanisms of chemoresistance and aims to develop more targeted treatment options and hopefully prevent recurrence for breast cancer patients.

Borriello stressed that nothing ever comes from just one principal investigator. “This award reflects a unique and wonderful supportive and collaborative environment at Temple and Fox Chase. This award absolutely would not have been possible without the support of colleagues and mentors,” she said.

Obeid, co-principal investigator Joseph Picone, PhD, and their team plan to use artificial intelligence to analyze cancer biopsy results to create more efficient reports for pathologists. The AI will estimate the stage of any cancers detected and provide supporting evidence for the pathologist to consider.

Obeid and Picone

“I’m very grateful for this funding from PBCC, which will allow us to push our research in biomedical signal processing and biomedical data analytics in new directions,” said Obeid, who also holds a secondary appointment in Temple’s Bioengineering Department.

Formed in 1993 by a group of breast cancer survivors, the PBCC advocates for the over 14,000 women in Pennsylvania diagnosed every year with breast cancer and serves as a resource for the hundreds of thousands more women currently living with the disease. PBCC does this through statewide educational programming and legislative advocacy. It has awarded more than $5.5 million to outstanding cancer researchers through its Research Grants Initiative.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427